<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>An Epigenetic Study of Treatment Effects and Environmental Factors in Schizophrenia and Bipolar Disorder</title>
    <meta charset="utf-8" />
    <meta name="author" content="Jonelle Villar - PhD Candidate" />
    <meta name="date" content="2024-04-04" />
    <script src="FoU_pres_files/header-attrs/header-attrs.js"></script>
    <link href="FoU_pres_files/tile-view/tile-view.css" rel="stylesheet" />
    <script src="FoU_pres_files/tile-view/tile-view.js"></script>
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
    <link rel="stylesheet" href="yellow_dots.css" type="text/css" />
    <link rel="stylesheet" href="extra.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# An Epigenetic Study of Treatment Effects and Environmental Factors in Schizophrenia and Bipolar Disorder
## Monthly FoU Meeting üå∑ <br/>
### Jonelle Villar - PhD Candidate
### April 4, 2024

---






<div>
<style type="text/css">.xaringan-extra-logo {
width: 250px;
height: 250px;
z-index: 0;
background-image: url(slides/UiBlogoMED_gray_v_Eng.png);
background-size: contain;
background-repeat: no-repeat;
position: absolute;
top:2em;right:2em;
}
</style>
<script>(function () {
  let tries = 0
  function addLogo () {
    if (typeof slideshow === 'undefined') {
      tries += 1
      if (tries < 10) {
        setTimeout(addLogo, 100)
      }
    } else {
      document.querySelectorAll('.remark-slide-content:not(.title-slide):not(.inverse):not(.hide_logo)')
        .forEach(function (slide) {
          const logo = document.createElement('div')
          logo.classList = 'xaringan-extra-logo'
          logo.href = null
          slide.appendChild(logo)
        })
    }
  }
  document.addEventListener('DOMContentLoaded', addLogo)
})()</script>
</div>


&lt;style type="text/css"&gt;

.small { 
  font-size: 0.75em
}  

.bitty { 
    font-size: 1.25em;
}

.enlarge { 
    font-size: 1.5em;
}

.fade {
  opacity: 0.66;
}

&lt;/style&gt;

---

background-image: url(slides/Kelly1.png)
background-position:75% 70%
background-size: 650px

class: top left
##Ett P√•sken√∏tt 
.enlarge["Astronaut Scott Kelly showed altered gene expression after one year in space, &lt;br&gt; but not his twin on earth."]

.footnote[The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight, Science, 2019]

---
class: hide_logo

background-image: url(slides/Smigielski.png)
background-position:cover
background-size: 700px

.footnote[Smigielski, _et al_, Molecular Psychiatry, 2020]

---


class: top left
### **DNA methylation** &lt;br&gt; &lt;br /&gt;

.pull-left[

![molecule](slides/chemMol.jpeg)
] 

.pull-right[

![histones](slides/dna-methylation-histones.jpeg)
] 

---
background-image: url(slides/cellsformat.png)
background-position:50% 65%
background-size: 750px

class: top, left
### DNA derived from leukocytes

---

###General aim of this PhD work
.enlarge[
 - To identify epigenetic marks (CpGs) associated with psychosis and treatment effects. &lt;br /&gt;
]

###Specific questions
.bitty[
- Does **time-of-blood draw** impact the association of SCZ vs controls on cell-type proportions? &lt;br&gt; &lt;br /&gt;
- What common and specific CpGs are seen following **antipsychotic** drug treatment for psychosis? &lt;br&gt; &lt;br /&gt;

]  

---
###Project 1
 .enlarge[Does **time-of-blood draw** impact the association of SCZ vs controls on cell-type proportions?

* Background &lt;br&gt;&lt;br /&gt;
  - SCZ is associated with altered cell-type proportions (Hannon _et al._, 2021) &lt;br&gt;&lt;br /&gt;
    - Immune cell alterations (NLR); age, gender, smoking, medication &lt;br&gt;&lt;br /&gt;
    - Disrupted diurnal (circadian) rhythms 
  ]
---
background-image: url(slides/diurnal_seasonal4.png)
background-position:50% 75%
background-size: 700px


class: left top
### Diurnal and seasonal cellular fluctuations 


.footnote[adapted: Oh _et al._, Geonome Biology, 2019; Wyse _et al._ iScience, 2021]

---
###Circadian rhythms and "chrono-epigenetics" &lt;br&gt; &lt;br&gt; 

.bitty[
- Morning light strong activator of clock genes and physiological processes &lt;br&gt; &lt;br&gt;
- Circadian clock genes co-evolved with the methyl cycle (Fustin, _et al._, 2020) &lt;br&gt; &lt;br&gt;
- Chrono-epigenetics: &lt;br&gt; &lt;br&gt;
    - temporal dynamics of epigenetic processes &lt;br&gt; &lt;br&gt;
    - oscillating CpGs contribute to epigenetic variability (Oh, E. &amp; Petronis, 2021)
]

---

class: top left 
### Oscillating CpGs
.center[&lt;img src=slides/osc_modC.gif width="40%"&gt;]


---

background-image: url(slides/Oh2019cc.png)
background-position:60% 35%
background-size: 725px

class: left top
### **Epigenetic oscillations**&lt;br&gt;&lt;br&gt; &lt;br&gt; &lt;br&gt; &lt;br&gt; &lt;br&gt;

.bitty[
* Gray boxes - "office hours"
* Black curves - oscillation profiles
* Red dots - randomly selected blood-draw time 

]


.footnote[Fig.adapted: Oh _et al._, Genome Biology, 2019]


---

###Method of analysis 

.bitty[
1. Selected European SCZ cases &amp; controls with recorded time-of-blood draw (n=729) &lt;br&gt; &lt;br&gt;
1. Calculated variable ‚Äúhours from 07:00 baseline‚Äù &lt;br&gt; &lt;br&gt;
1. Samples matched for age and sex &lt;br&gt; &lt;br&gt;
1. Compared full day vs half day &lt;br&gt; &lt;br&gt;
1. Sub-analysis: Neutrophil-to-lymphocyte ratio (NLR) &lt;br&gt; &lt;br&gt;
1. Sub-analysis: Medication-free SCZ cases
]

---

background-image: url(slides/2021_08_05_Histogram_n729.png)
background-position: 50% 45% 
background-size: 425px

class: left, top
###Distribution of recorded blood draws (n=729) &lt;br&gt; &lt;br&gt; &lt;br&gt; &lt;br&gt; &lt;br&gt; &lt;br&gt; &lt;br&gt; &lt;br /&gt; 


- __Model 1: Cell-type proportions ~  Case_Control + Age + Sex + Smoking_score + Methbatch + ùú∫__
- __Model 2: Cell-type proportions ~ Case_Control + Age + Sex + Smoking_score + Methbatch + Hours_from_baseline + ùú∫__

---
background-image: url(slides/2021_09_04_Table.CorrectPvalsTeal.png)
background-position: 25% 45% 
background-size: 400px

class: top left 
###Results

.pull-right[

.enlarge[__Full day (n=729)__]

.bitty[
- P-values reduced significance in Model 2
- Effect sizes diminished in Model 2
]

.enlarge[__Half day (n=524)__]

.bitty[
- P-values: no significant change 
- Effect sizes: no change
]
]

---
class: top left 
###Results: Sub-analyses 

.enlarge[
* __NLR__: significant ass. in all trials (_p_ &lt;.001) &lt;br&gt; &lt;br&gt;
* __Medication-free cases__: __full-day trial__: Neu &amp; CD4T significant ass., yet moderated effect size; __half-day trial__: Neu &amp; CD4T remained significant, no change in effect size (_p_ &lt;.01)

###Conclusion Project 1:

To reduce epigenetic variation associated with time-of-blood draw and the circadian cycling of white blood cells
* either correct for __cell-types__ - or for __time-of-blood draw__
]

---
###Project 2 &lt;br&gt; &lt;br /&gt; 
 .enlarge[What common and specific CpGs are seen following **antipsychotic** treatment for psychosis?]


---

background-image: url(slides/clinical_course.png)
background-position: 50% 75% 
background-size: 750px

class: top left 

### Background - Psychosis
.enlarge[Symptoms:
* Hallucinations, delusions, social withdrawal and apathy
* **Loss of insight** into their condition] 

.footnote[McCutcheon, _et al._, JAMA Psychiatry, 2020; Elanjithara, _et al._, Advances in Psych Treatment, 2011]

---
class: top left 

### Background - Antipsychotics
.enlarge[Antipsychotics (AP) first line of treatment 
* Dopamine dysregulation &amp;#x02192; psychosis and mechanism of AP action &lt;br&gt; &lt;br /&gt;
* 1st generation AP: dopamine receptor antagonists &lt;br&gt; &lt;br /&gt;
* 2nd generation AP: dopamine and serotonin receptor antagonists &lt;br&gt; &lt;br /&gt;
* Different dopamine binding affinities and profiles &lt;br&gt; &lt;br /&gt;
* Side-effect profile: weight gain, sedation, glucose and lipid metabolism disturbances 
]
    
.footnote[Kaar _et al._, Neuropharmacology, 2020]        
---

background-image: url(slides/Aringhieri2.jpg)
background-position: 60% 75%
background-size: 775px

class: left, top

###Molecular targets

.footnote[Aringhieri _et al_, Pharmacology &amp; Therapeutics, 2018]

---

### EWAS findings and status  
 .enlarge[Genes:_DRD2_, _DRD3_, _HTR2A_, _SLC6A4_, _COMT_] &lt;br&gt; &lt;br /&gt;
 
.bitty[__Challenges__:
* Variety of methods, tissues assayed, study designs, sample sizes &lt;br&gt; &lt;br /&gt; 
* No uniform identification/reporting of hyper- or hypo-methylation  &lt;br&gt; &lt;br&gt;
* Lack of consistency in reporting medication &lt;br&gt; &lt;br /&gt; 
* Studies of AP monotherapy are lacking  &lt;br&gt; &lt;br&gt;
* Studies of AP serum values associated with DNAm are lacking.
 
]

.footnote[Burghardt _et.al_, Pharmacotherapy, 2020; Zhang &amp; Malhotra, Current Psychiatry Reports, 2018]

---
class: top left
###Method of analysis 

.bitty[**To identify specific effects**: 
1. Select European SCZ &amp; BPD cases - AP monotherapy with positive serum values (n=433) &lt;br&gt; &lt;br&gt;
 - Aripiprazole (n = 62)
 - Olanzapine   (n = 192)
 - Quetiapine   (n = 122)  
 - Risperdal    (n = 57) &lt;br&gt; &lt;br&gt;
1. No need to correct for time-of-blood draw as these are all cases &lt;br&gt; &lt;br&gt;
1. Model: DNAm ~ AP_serum_value + OtherMeds + Age + Sex + Smoking_score + Cells +ùú∫&lt;br&gt; &lt;br&gt;
1. Identify CpGs, associated genes, and differentially methylated regions (DMRs) &lt;br&gt; &lt;br&gt;
1. Gene set enrichment and pathway analysis  
]

---

class:top left

### Model selected for Quetiapine  &lt;br&gt;&lt;br&gt;
* .enlarge[Serum values &gt; 0, n = 92] &lt;br&gt;&lt;br&gt; &lt;br&gt;

.enlarge[DNAm ~ Serum1 + Serum2 + Serum_Lithium + Age + Sex + SmokingScore + Cells +ùú∫]  

---
background-image: url(slides/Que_n92_Mod1_manhatt.png)
background-position: 75% 75%
background-size: 500px


class: top left
### Preliminary results: &lt;br&gt; 

.enlarge[**GLT8D1: Glycosyltransferase 8 Domain Containing 1**]

.pull-left[.enlarge[CpG: Pval = 2.25e-08 &lt;br&gt; &lt;br&gt;
adj BH Pval = 0.017 ]
]

---
background-image: url(slides/Mealer_glyco.jpg)
background-position: 20% 75%
background-size: 325px

class: left top 

### Dysregulated glycosylation in SCZ 

.pull-right[.enlarge[
GluA1,***GRIA1***: glutamate; cell-surface expression &lt;br&gt; &lt;br /&gt; 
GluN2A,***GRIN2A***: glutamate; receptor localization &lt;br&gt; &lt;br /&gt;
CaV1.2,***CACNA1C***: calcium;cell-surface expression &lt;br&gt; &lt;br /&gt;
DR2,***DRD2***: dopamine;cell-surface expression
]
]

.pull-right[.footnote[Mealer _et al_, Molecular Psychiatry, 2020]]


---
class: top left
### Further steps &lt;br&gt; &lt;br /&gt;

.enlarge[
* Specific effects: Continue analyses with other mono therapies&lt;br&gt; &lt;br /&gt;
* Common effects: Compare antipsychotic therapy vs non antipsychotic use
]

---

background-image: url(slides/Martens2.jpg)
background-position: 12% 65%, 20% 10%
background-size: 600px

class: top center hide_logo

# Acknowledgements

.pull-right[.bitty[
**Supervisor St√©phanie **&lt;br&gt;&lt;br&gt;
**Co-Supervisor Anne-Kristin**&lt;br&gt;&lt;br&gt;
**Colleagues in The Martens Group**&lt;br&gt;&lt;br&gt;
**Dept. of Clinical Science II** &lt;br&gt;&lt;br&gt;
**Dr Einar Martens Research Group** &lt;br&gt;
**for Biological Psychiatry** &lt;br&gt;&lt;br&gt;
**NORMENT** 
]
]

---
class: top center hide_logo

background-image: url(slides/red_egg2.png)
background-position: 50% 75%
background-size: 375px

###God P√•ske til alle!













    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script>var slideshow = remark.create({
"slideNumberFormat": "%current%",
"highlightStyle": "github",
"highlightLines": true,
"ratio": "16:9",
"countIncrementalSlides": true
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
